Boston Scientific (NYSE:BSX) is planning a fourth building at its Maple, Grove, Minn. campus to support expanded nitinol stent manufacturing.
The Maple Grove Planning Commission is scheduled to review project plans tonight for the roughly 76,000 ft2 building.
“This new building will allow for movement of some production currently taking place in existing buildings on that campus, and support increased needs for growing product lines such as the Watchman left atrial appendage closure device, Eluvia drug-eluting vascular stent system and Innova stent system,” Boston Sci said in a statement that spokesperson Kate Haranis shared with DDBN‘s sister site MassDevice.
